{
  "drug_name": "Retapamulin",
  "tradename": "Altabax",
  "usage_and_dosing": {
    "description": [
      "Member of pleuromutilin class; a topical antibacterial.",
      "For therapy of impetigo due to Strep. pyogenes or Staph. aureus.",
      "Microbiologic success in 90% of Staph. aureus infections and 97% of Strep. pyogenes infections (J Am Acad Derm 55:1003, 2006).",
      "Package insert says do not use for MRSA (not enough patients in clinical trials). Retapamulin active in vitro vs MRSA.",
      "Reference: Clin Infect Dis 49:1541, 2009, Clin Micro Rev 30(3): 827, 2017."
    ],
    "adult_dose": "1% ointment; apply to affected area bid x 5 days",
    "pediatric_dose": {
      "dose_age_gt_28_days": "Age \u22659 mon: apply q12h x5 days (max area up to 2% BSA)",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "guidance": [
      "Body weight and Creatinine Clearance calculations",
      "CrCl = Creatinine clearance (mL/min)",
      "CAPD = Continuous Ambulatory Peritoneal Dialysis",
      "CRRT = Continuous Renal Replacement Therapy",
      "AD = after hemodialysis",
      "SLED = sustained low efficiency dialysis"
    ],
    "half_life_hrs_renal_function_normal": "No data",
    "half_life_hrs_esrd": "No data",
    "dose_renal_function_normal": "Apply q12h x5 days",
    "crcl_or_egfr": "No dosage adjustment for renal impairment",
    "hemodialysis": "No data",
    "capd": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_class_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_class_b": "No dosage adjustment",
    "severe_impairment_child_pugh_class_c": "No dosage adjustment"
  },
  "adverse_effects": [
    "Pruritis, at application site, 2%.",
    "Local irritation."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "B",
    "use_during_lactation": "Safety not established, avoid use"
  },
  "antimicrobial_spectrum": [
    "Staph. aureus",
    "Strep. pyogenes",
    "Active vs. some Staph. aureus strains resistant to Mupirocin"
  ],
  "pharmacology": {
    "pk_pd_index": "No data",
    "pharmaceutical_preparations": "1% ointment",
    "food_rec_po_drugs": "",
    "oral_absorption_percent": "-",
    "tmax_hr": "-",
    "peak_serum_conc_ug_ml": "Low, not always measurable",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "94",
    "volume_of_distribution_vd": "No data",
    "avg_serum_t1_2_hr": "No data",
    "elimination": "Metabolized",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "No data"
  },
  "enzyme_transporter_mediated_interactions": {
    "cy_p450s_that_drug_is_a_substrate_for": "CYP3A4",
    "transporters_that_drug_is_a_substrate_for": "-",
    "ug_ts_that_drug_is_a_substrate_for": "-",
    "cy_p450s_inhibited_by_drug": "-",
    "transporters_inhibited_by_drug": "-",
    "ug_ts_inhibited_by_drug": "-",
    "cy_p450s_induced_by_drug": "-",
    "transporters_induced_by_drug": "-",
    "ug_ts_induced_by_drug": "-",
    "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
    "Avoid coadministration with strong CYP3A4 inhibitors in children <24 months old."
  ],
  "comments": [
    "Not for intranasal, intravaginal, oral or ophthalmic use."
  ]
}